Login to Your Account

Worries of abuse lead to tight yes vote for Pfizer's Troxyca ER

By Mari Serebrov
Regulatory Editor

Wednesday, June 8, 2016

After wrestling once again with what passes muster as abuse deterrence, two FDA advisory committees voted 9-6 Wednesday to recommend approval of Pfizer Inc.'s Troxyca ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment when alternative options are inadequate.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription